Quotient Sciences
Ruddington, Nottingham, NG11 6JS, United Kingdom
NCT Number: NCT03877952
This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of 14C-CORT125281 in healthy participants.
Looking for future studies?
Notify Me30 year–65 year
Male
Interventional
Phase 1
Ruddington, Nottingham, NG11 6JS, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
Time frame: Until the mass balance criteria for all participants have been met (estimated up to 10 days)
Time frame: Until the mass balance criteria for all participants have been met (estimated up to 10 days)
Time frame: Until the mass balance criteria for all participants have been met (estimated up to 10 days)
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 8 after dosing
Time frame: Until the mass balance criteria for all participants have been met (estimated up to 10 days)
Time frame: Until the mass balance criteria for all participants have been met (estimated up to 10 days)
Corcept Therapeutics
Industry
A Phase 1 Open-label, Single-dose Study Designed to Assess the Mass Balance Recovery and Metabolite Profile and to Identify Metabolite Structures for [14C]-CORT125281 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06944002
Healthy
Rotterdam, Netherlands
View Trial DetailsNCT05537363
Cognition Disorders, Cognitive Dysfunction
Taipei, Taiwan
View Trial DetailsNCT04455334
Brain Diseases, Cardiovascular Diseases
Taipei, Taiwan
View Trial DetailsNCT03923205
Diabetes Mellitus, Diabetes Mellitus, Type 2
Aberdeen, United Kingdom
View Trial Details